LINSITINIB SIDE EFFECTS NO FURTHER A MYSTERY

The LIDS demo achieved its Principal endpoint with statistical importance for your 150mg BID dose. Linsitinib in this trial validated the protection profile observed from the prior oncology reports and importantly shown a positive security profile on vital adverse activities (AEs) of fascination with the IGF-1R target including hearing impairment,